Related Articles
Anti-CD19 CAR T-cell therapy for patients with primary or secondary CNS lymphoma
Here, we summarize an analysis of CD19-targeting CAR T-cell therapy in patients with PCNSL or SCNSL, presented by Ossami Saidy during the 50th Annual Meeting…
Camrelizumab plus GEMOX as salvage therapy for R/R cHL: Results from a phase II trial
Here, we summarize results from a phase II trial assessing the safety and efficacy of camrelizumab in combination with GEMOX followed by auto-HSCT in patients…
What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T cell therapy
The Lymphoma Hub and Multiple Myeloma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the…
Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study
Here, we summarize a health-related quality of life and patient-reported outcomes analysis from the phase II PILOT trial, published by Gordon et al. in Haematologica.
Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free…
Waldenström’s macroglobulinemia | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received…
What are the strategies to manage toxicities with CAR T-cell therapies?
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology,…
Venetoclax monotherapy for patients with R/R CLL: Results from the phase III VENICE-1 trial
Here we summarize the results from the VENICE-1 trial evaluating venetoclax monotherapy in patients with R/R CLL, published by Kater et al.1 in Lancet Oncology.
SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US.…